Background pattern
Cholib 145 mg/20 mg FILM-COATED TABLETS

Cholib 145 mg/20 mg FILM-COATED TABLETS

This page is for general information. Consult a doctor for personal advice. Call emergency services if symptoms are severe.
About the medicine

How to use Cholib 145 mg/20 mg FILM-COATED TABLETS

Introduction

Package Leaflet: Information for the User

Cholib 145 mg/20 mg film-coated tablets

fenofibrate/simvastatin

Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.

  • Keep this leaflet, you may need to read it again.
  • If you have any further questions, ask your doctor or pharmacist.
  • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
  • If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet.

Contents of the pack:

  1. What Cholib is and what it is used for
  2. What you need to know before you take Cholib
  3. How to take Cholib
  4. Possible side effects
  5. Storage of Cholib
  6. Contents of the pack and other information

1. What Cholib is and what it is used for

Cholib contains two different active substances: fenofibrate (belonging to the group of so-called 'fibrates') and simvastatin (belonging to the group of so-called 'statins'). Both are used to reduce the levels of total cholesterol, "bad" cholesterol (LDL) and fatty substances called triglycerides in the blood. Both also increase the levels of "good" cholesterol (HDL).

What should I know about cholesterol and triglycerides?

Cholesterol is one of the different fats present in the blood. Total cholesterol is mainly made up of LDL cholesterol and HDL cholesterol.

LDL cholesterol is known as "bad" cholesterol because it builds up in the walls of the arteries and can form plaques. Over time, the buildup of plaques can block the arteries.

HDL cholesterol is known as "good" cholesterol because it helps prevent "bad" cholesterol from building up in the arteries and protects against heart disease.

Triglycerides are another type of fat present in the blood that can increase the risk of heart problems.

In most people, problems with cholesterol or triglycerides go unnoticed at first. Your doctor can find out your lipid levels with a simple blood test. Visit your doctor regularly to have your lipid levels checked.

Cholib is used in adults with a high risk of problems such as heart attack or stroke who have high levels of the two types of fat (triglycerides and LDL cholesterol) in the blood. It is given to reduce triglycerides and increase "good" cholesterol (HDL cholesterol) in patients whose "bad" cholesterol (LDL cholesterol) has already been controlled using only simvastatin with a dose of 20 mg.

You should follow a low-fat diet or take other measures (e.g., exercise, weight loss) during treatment with Cholib.

2. What you need to know before you take Cholib

Do not take Cholib:

  • if you are allergic to fenofibrate or simvastatin or any of the other ingredients of Cholib (listed in section 6)
  • if you are allergic to peanuts, peanut oil, soy lecithin, or related substances
  • if you have had an allergic reaction or skin lesions caused by sunlight or UV light while taking other medications (these medications include other fibrates and an anti-inflammatory medication called "ketoprofen")
  • if you have liver or gallbladder problems
  • if you have pancreatitis (inflamed pancreas that causes abdominal pain), which is not caused byhigh levels of fat in the blood
  • if you have moderate or severe kidney problems.
  • if you have a history of muscle problems during treatment to reduce blood fat levels with either of the active substances of this medicine or with other statins (such as atorvastatin, pravastatin, or rosuvastatin) or fibrates (such as bezafibrate, gemfibrozil)
  • if you are already taking the following medications:
  • danazol (an artificial hormone used to treat endometriosis)
  • cyclosporin (a medication commonly used in patients undergoing organ transplants)
  • itraconazole, ketoconazole, fluconazole, or posaconazole (medications for fungal infections)
  • HIV protease inhibitors such as indinavir, nelfinavir, ritonavir, and saquinavir (medications used in HIV and AIDS infection)
  • glecaprevir or pibrentasvir (used to treat hepatitis C virus infection)
  • erythromycin, clarithromycin, or telithromycin (medications for bacterial infections)
  • nefazodone (a medication for depression)
  • if you are already undergoing treatment and will continue treatment with:
  • a fibrate (e.g., gemfibrozil)
  • a statin (a medication to reduce blood fat levels, e.g., simvastatin, atorvastatin)
  • if you are under 18 years old
  • if you are pregnant or breastfeeding

Do not take Cholib if any of the above situations apply to you. If in doubt, consult your doctor or pharmacist again.

Warnings and precautions

Consult your doctor or pharmacist before taking Cholib if:

  • you have an underactive thyroid gland (hypothyroidism)
  • you are scheduled to undergo surgery. You may need to stop taking Cholib for a short period.
  • you drink large amounts of alcohol (more than 21 units (210 ml) of pure alcohol per week)
  • you have chest pain and difficulty breathing. These can be signs of a blood clot in the lung (pulmonary embolism)
  • you have severe lung disease
  • you have kidney disease
  • you or a close relative have a hereditary muscle problem
  • you are taking or have taken in the last 7 days a medication called fusidic acid (an antibiotic)
  • you are taking antiviral agents for hepatitis C such as elbasvir or grazoprevir (used to treat hepatitis C virus infection)

If any of the above situations apply to you, consult your doctor or pharmacist before taking Cholib. If in doubt, consult your doctor or pharmacist again.

Also, inform your doctor or pharmacist if you experience persistent muscle weakness. Further tests and medication may be necessary to diagnose and treat this problem.

Your doctor will perform a blood test before you start taking Cholib to check how well your liver is working.

Your doctor may also want to perform blood tests to check how well your liver is working after you start taking Cholib.

While taking this medication, your doctor will closely monitor you if you have diabetes or are at risk of developing the disease. You are likely to be at risk of developing diabetes if you have high levels of sugar and fat in your blood, are overweight, and have high blood pressure.

Your doctor may perform a blood test to check your muscles before and after starting treatment.

Children and adolescents

Cholib should not be given to children or adolescents (under 18 years old).

Taking Cholib with other medicines:

It is especially important that you inform your doctor or pharmacist if you are taking, have recently taken, or might take other medicines. This also applies to medicines without a prescription, including herbal medicines.

Inform your doctor or pharmacist if you are taking any of the following medicines:

  • danazol (an artificial hormone used to treat endometriosis)
  • cyclosporin (a medication commonly used in patients undergoing organ transplants)
  • itraconazole, ketoconazole, fluconazole, or posaconazole (medications for fungal infections)
  • HIV protease inhibitors such as indinavir, nelfinavir, ritonavir, and saquinavir (medications used in HIV and AIDS infection)
  • glecaprevir or pibrentasvir (used to treat hepatitis C virus infection)
  • erythromycin, clarithromycin, or telithromycin (medications for bacterial infections)
  • nefazodone (a medication for depression)
  • a fibrate (e.g., fenofibrate, gemfibrozil)
  • a statin (e.g., simvastatin, atorvastatin)

Do not take Cholib if any of the above situations apply to you. If in doubt, consult your doctor or pharmacist again.

In particular, inform your doctor or pharmacist if you are taking any of the following medicines (taking Cholib with any of these medicines may increase the risk of muscle problems):

  • high doses of at least 1 gram per day of niacin (nicotinic acid) or a treatment that contains niacin (a medication to reduce blood fat levels)
  • colchicine (a medication used to treat gout)

Do not take fusidic acid (an antibiotic) while using this medication.

Apart from the medicines mentioned above, inform your doctor or pharmacist if you are taking, have recently taken, or might take any of the following medicines:

  • anticoagulants such as warfarin, fluindione, phenprocoumon, or acenocoumarol (medications to prevent blood clots)
  • pioglitazone (a particular class of medications for treating diabetes)
  • rifampicin (a medication used to treat tuberculosis)
  • elbasvir or grazoprevir (used to treat hepatitis C virus infection)

If any of the above situations apply to you, consult your doctor or pharmacist before taking Cholib. If in doubt, consult your doctor or pharmacist again.

Cholib with food and drinks

Grapefruit juice contains one or more components that alter the way the body uses Cholib. Do not take grapefruit juice with Cholib as it may increase your risk of muscle problems.

Pregnancy and breastfeeding

  • Do not take Cholib if you are pregnant, trying to become pregnant, or think you may be pregnant. If you become pregnant while taking Cholib, stop taking it immediately and consult your doctor.
  • Do not take Cholib if you are breastfeeding or plan to breastfeed, as it is unknown whether the medication passes into breast milk.

If you are pregnant or breastfeeding, think you may be pregnant, or are planning to become pregnant, consult your doctor or pharmacist before using this medication.

Driving and using machines:

Cholib is not expected to affect your ability to drive or use tools or machines. However, it should be taken into account that some people may feel dizzy after taking Cholib.

Important information about some of the ingredients of Cholib

Cholib contains types of sugars called lactose and sucrose. If your doctor has told you that you have an intolerance to some sugars, talk to them before taking this medicine.

Cholib contains soy lecithin. If you are allergic to peanuts, soy, or peanut oil, do not use Cholib.

Cholib contains orange yellow S (E110), which may cause allergic reactions.

3. How to take Cholib

Follow the instructions for administration of this medicine exactly as prescribed by your doctor.

In case of doubt, consult your doctor or pharmacist again.

Your doctor will determine the appropriate dose for you depending on your condition, current treatment, and personal risk factors.

The usual dose is one tablet per day.

You can take Cholib with or without food.

The tablets should be swallowed with a glass of water.

The tablets should not be crushed or chewed.

You should follow a low-fat diet or take other measures (e.g., exercise, weight loss) while taking Cholib.

If you take more Cholib than you should

If you have taken more Cholib than you should or if someone else has taken your medicine, inform your doctor or pharmacist or contact the nearest hospital.

If you forget to take Cholib

Do not take a double dose to make up for forgotten tablets. Take the next tablet at the usual time the next day. If you are concerned, consult your doctor or pharmacist.

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

4. Possible Adverse Effects

Like all medicines, this medicine may cause adverse effects, although not all people suffer from them.

  • Any muscle pain, pain on palpation, or unexplained weakness may be a sign of muscle degradation. Therefore, if you develop any of these symptoms, inform your doctor immediately, as rare cases of serious muscle problems, including muscle degradation that causes kidney damage, have occurred; and very rare deaths have occurred. Compared to a fibrate or statin taken alone, the risk of muscle degradation increases when taking these two medicines together, as is the case with Cholib. It is higher in women or patients over 65 years old.

Some patients have experienced the following serious adverse effects while taking fenofibrate or simvastatin (both active ingredients of Cholib):

  • hypersensitivity reactions (allergic) including: swelling of the face, tongue, and throat, which can cause difficulty breathing (angioedema) (rare)
  • a severe allergic reaction that causes difficulty breathing or dizziness (anaphylactic reaction) (very rare)
  • hypersensitivity reaction to Cholib with symptoms such as: pain or inflammation of the joints, inflammation of blood vessels, unusual bruising, swelling, and skin rashes, hives, skin sensitivity to sunlight, fever, hot flashes, difficulty breathing, and feeling of discomfort, symptoms of a disease similar to lupus (including rash, joint disorders, and effects on white blood cells)
  • cramps or pain, discomfort, or muscle weakness, muscle rupture: these can be signs of inflammation or muscle degradation, which can cause kidney damage or even death
  • stomach pain: may be a sign that your pancreas is inflamed (pancreatitis)
  • chest pain and difficulty breathing: these can be signs of a blood clot in the lung (pulmonary embolism)
  • pain, redness, or swelling of the legs: can be signs of a blood clot in the leg (deep vein thrombosis)
  • yellowing of the skin and whites of the eyes (jaundice) or an increase in liver enzymes: can be signs of an inflamed liver (hepatitis and liver failure)
  • increased sensitivity of the skin to sunlight, sunlamps, and tanning beds
  • rash that can occur on the skin or ulcers in the mouth (drug-induced lichenoid eruptions)

If you experience any of the above serious adverse effects, stop taking Cholib and inform your doctor immediately or go to the emergency department of the nearest hospital; you may need urgent medical treatment.

Some patients have experienced the following adverse effects while taking Cholib, fenofibrate, or simvastatin:

Very frequent adverse effects (may affect more than 1 in 10 people):

  • increase in "creatinine" level in the blood (substance excreted by the kidneys)
  • increase in blood levels of "homocysteine" (an excessive amount of this amino acid in the blood is related to a higher risk of coronary heart disease, stroke, and peripheral vascular disease, although a causal relationship has not been established)

Frequent adverse effects (may affect up to 1 in 10 people):

  • increase in platelet count in blood
  • elevations in liver function tests (transaminases)
  • digestive disorders (stomach pain, nausea, vomiting, diarrhea, and flatulence)
  • upper respiratory tract infection

Uncommon adverse effects (may affect up to 1 in 100 people):

  • muscle problems
  • gallstones
  • rash, itching, red spots on the skin
  • headache
  • sexual problems

Rare adverse effects (may affect up to 1 in 1,000 people):

  • low red blood cell count (anemia)
  • numbness or weakness of arms and legs
  • confusion
  • feeling of dizziness
  • feeling of fatigue (asthenia)
  • increase in "urea" (produced by the kidneys) reflected in tests
  • increase in "gamma glutamyltransferase" (produced by the liver) reflected in tests
  • increase in "alkaline phosphatase" (produced by the biliary system) reflected in tests
  • increase in "creatine phosphokinase" (produced by muscle) reflected in tests
  • decrease in hemoglobin (which carries oxygen in the blood) and white blood cells - reflected in tests
  • difficulty sleeping
  • poor memory or memory loss
  • hair loss
  • constipation
  • dyspepsia
  • blurred vision and vision impairment

Very rare adverse effects (may affect up to 1 in 10,000 people):

  • gynecomastia (enlargement of breast tissue in men)

The following adverse effects have also been reported, but their frequency cannot be estimated from the available data (frequency not known):

  • severe allergic skin rash with blisters
  • complications of gallstones such as colic, caused by the presence of stones in the bile duct, infection of the bile ducts or gallbladder
  • diabetes mellitus
  • erectile dysfunction
  • feeling of depression
  • sleep disorders, including nightmares
  • specific lung disease with breathing difficulties (called interstitial lung disease)
  • constant muscle weakness
  • increase in "glycosylated hemoglobin" and blood glucose levels (markers of blood glucose control in diabetes mellitus) reflected in tests

Reporting of Adverse Effects

If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect that is not listed in this prospectus. You can also report them directly through the national reporting system included in Appendix V. By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.

5. Storage of Cholib

Keep this medicine out of the sight and reach of children.

Do not use Cholib after the expiration date shown on the box and blister after CAD.

The expiration date is the last day of the month indicated.

Store below 30 °C.

Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.

6. Package Contents and Additional Information

Composition of Cholib

The active ingredients are fenofibrate and simvastatin. Each tablet contains 145 mg of fenofibrate and 20 mg of simvastatin.

This medicine contains less than 1 mmol of sodium (23 mg) per tablet, i.e., it is essentially "sodium-free".

The other ingredients are:

Tablet core:

Butylhydroxyanisole (E320), lactose monohydrate, sodium lauryl sulfate, pregelatinized corn starch, sodium docusate, sucrose, citric acid monohydrate (E330), hypromellose (E464), crospovidone (E1202), magnesium stearate (E572), silicified microcrystalline cellulose (composed of microcrystalline cellulose and anhydrous colloidal silicon dioxide), ascorbic acid (E300).

Coating:

Partially hydrolyzed polyvinyl alcohol (E1203), titanium dioxide (E171), talc (E553b), soybean lecithin (E322), xanthan gum (E415), red iron oxide (E172), yellow iron oxide (E172), orange yellow S (E110).

Appearance of Cholib and Package Contents

Oval, biconvex, film-coated tablet, dark beige in color, with the inscription 145/20 on one side. The diameter is approximately 19.3 x 9.3 mm and the weight of the tablet is about 734 mg.

The tablets are presented in cardboard boxes with blisters containing 10, 30, or 90 tablets.

Only some pack sizes may be marketed.

Marketing Authorization Holder and Manufacturer

Marketing Authorization Holder:

Viatris Healthcare Limited, Damastown Industrial Park, Mulhuddart, Dublin 15, Dublin, Ireland

Manufacturer:

Mylan Laboratories SAS, Route de Belleville - Lieu-dit Maillard, 01400 Châtillon-sur-Chalaronne - France.

Mylan Hungary Kft., Mylan utca 1, Komárom 2900, Hungary

You can request more information about this medicine by contacting the local representative of the marketing authorization holder.

België/Belgique/Belgien

Viatris

Tél/Tel: + 32 (0)2 658 61 00

Ireland

Mylan Ireland Limited

Tel: + 353 1 8711600

Norge

Viatris AS

Tlf: + 47 66 75 33 00

Text in Bulgarian language with contact information of Майлан-ЕООД, including phone number +359-2-44-55-400

Ísland

Icepharma hf.

Sími: + 354 540 8000

Österreich

Viatris Austria GmbH

Tel: + 43 1 86390

Ceská republika

Viatris CZ s.r.o.

Tel: +420 222 004 400

Italia

Viatris Italia S.r.l.

Tel: + 39 (0) 2 612 46921

Polska

Viatris Healthcare Sp.zo.o.

Tel.: + 48 22 546 64 00

Danmark

Viatris ApS

Tlf: + 45 28 11 69 32

Κúπρος (Cyprus)

GPA Pharmaceuticals Ltd

Τηλ: +357 22863100

Portugal

Viatris d.o.o.

Tel: + 351 214 127 200

Deutschland

Viatris Healthcare GmbH

Tel: + 49 800 0700 800

Latvija

Viatris UAB

Tel: + 371 67 605 580

România

BGP Products SRL

Tel: + 40 372 579 000

Eesti

Viatris OÜ

Tel: +372 6363 052

Lietuva (Lithuania)

Viatris UAB

Tel: +370 52 051 288

Slovenija

Viatris d.o.o.

Tel: + 386 (0) 123 63 180

Ελλáδα

Viatris Hellas Ltd

Τηλ: + 30 2100 100 002

Luxembourg/Luxemburg

Viatris

Tél/Tel: + 32 (0)2 658 61 00

Slovenská republika

Viatris Slovakia s.r.o.

Tel: + 421 2 32 199 100

España

Viatris Pharmaceuticals, S.L.

Tel: + 34 900 102 712

Magyarország

Viatris Healthcare Kft.

Tel.: +36 1 465 2100

Suomi/Finland

Viatris Oy

Puh/Tel: + 358 20 720 9555

France

Viatris Santé

Tél: + 33 (0)1 40 80 15 55(0)1 56

64 10 70

Malta

V.J. Salomone Pharma Ltd

Tel: + 356 21 22 01 74

Sverige

Viatris AB

Tel: + 46 (0)8 630 19 00

Hrvatska

Viatris Hrvatska d.o.o.

Tel: + 385 1 23 50 599

Nederland

Mylan BV

Tel: + 31 (0)20 426 33 00

United Kingdom (Northern Ireland)

Mylan IRE Healthcare Ltd

Tel: +353 18711600

Date of the last revision of this prospectus:

Other sources of information

Detailed information about this medicine is available on the website of the European Medicines Agency (EMA): http://www.ema.europa.eu.

Get updates and exclusive offers

Be the first to know about new services, marketplace updates, and subscriber-only promos.

Follow us on social media
FacebookInstagram
Logo
Oladoctor
Find a doctor
Doctors by specialty
Services
Choose language
© 2025 Oladoctor. All rights reserved.
VisaMastercardStripe